隶属于 beth israel lahey health, inc.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- MIT researchers identified 24 immunogenic peptides from 13 tuberculosis proteins through large-scale screening, revealing new vaccine targets that stimulate strong T cell responses in people with prior TB infection. - BIDMC scientists developed a trivalent mRNA vaccine combining three previously untested TB antigens that outperformed the century-old BCG vaccine in animal models by reducing infection rates and bacterial spread. - Both research teams utilized mRNA vaccine technology to deliver their candidates, with the BIDMC vaccine planned for Phase 1 clinical trials as a potential breakthrough in TB prevention. - The advances address a critical global health need, as tuberculosis remains the world's deadliest infectious disease, killing over 1 million people annually with limited vaccine protection for adults.
• A groundbreaking study published in Nature Medicine reveals that physicians using AI language models demonstrated superior performance in patient care tasks compared to those using conventional resources. • Physicians utilizing AI spent approximately two minutes longer per case and showed reduced rates of mild-to-moderate harm potential (3.7% vs 5.3%) in their clinical decisions. • The research, led by BIDMC's AI Programs Director Dr. Adam Rodman, evaluated 92 physicians handling complex management reasoning tasks across five hypothetical patient cases.
